PGS Consensus Statement on management of Hepatitis B Virus Infection - 2003

Journal of the Pakistan Medical Association

Volumn 54, Issue 3, 2004, Pages 150-158

  Abbas, Z ^a   Jafri, W ^a   Shah, S H A ^a   Khokhar, N ^a   Zuberi, S J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS C ANTIBODY; HERBACEOUS AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 12; LAMIVUDINE; MONOCLONAL ANTIBODY; PEGINTERFERON; THYMOSIN ALPHA1;

AMINOTRANSFERASE BLOOD LEVEL; BLOOD DONOR; BLOOD TRANSFUSION; BREAST FEEDING; CLINICAL TRIAL; DIALYSIS; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; DRUG EFFICACY; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION CONTROL; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; NONHUMAN; ORGAN TRANSPLANTATION; PREVALENCE; PROPHYLAXIS; PUBLIC HEALTH; REVIEW; SEROCONVERSION; SEXUAL TRANSMISSION; SIDE EFFECT; ULTRASOUND; VACCINATION; VERTICAL TRANSMISSION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CARRIER STATE; DISEASE TRANSMISSION; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; PAKISTAN; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 1942470081     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Khan AA, Rehman KU, Haider Z, et al. Sero-markers of hepatitis B and C in patients with cirrhosis. J. Coll Phys Surg Pak 2002;12:105-7.
2. Umar M, Bushra HT, Younis N, et al. Clinical spectrum of chronic liver disease due to HBV, HCV and dual infection - a comparative study. Pak J. Gastroenterol 1999;13:1-3.
3. Abdul-Mujeeb S, Jamal Q, Khanani R, et al. Prevalence of hepatitis B surface antigen and HCV antibodies in hepatocellular carcinoma cases in Karachi, Pakistan. Trop Doct 1997;27:45-6
4. Andre F. Hepatitis B epidemiology in Asia: the Middle East and Africa. Vaccine 2000;18 (Suppl) 1:S20-2.
5. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
6. Khattak MF, Salamat N, Bhatti FA, Qureshi TZ. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. J Pak Med Assoc 2002;52:398-402.
7. Kakepoto GN, Bhally HS, Khaliq G, et al. Epidemiology of blood-borne viruses: a study of healthy blood donors in Southern Pakistan. Southeast Asian J Trop Med Public Health 1996;27:703-6.
8. Abdul-Mujeeb S, Aamir K, Mehmood K. Seroprevalence of HBV, HCV and HIV infections among college going first time voluntary blood donors. J Pak Med Assoc 2000;50:269-70.
9. Luby SP, Qamruddin K, Shah AA, et al. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol Infect. 1997;119:349-56.
10. Zuberi SJ, Lodi TZ, Samad F. Prevalence of hepatitis B surface antigen and antibody in healthy subjects and patients with liver disease. J Pak Med Assoc 1978;28:2-3.
11. Zuberi Z. Hepatitis B: Pakistani Perspective. National Consensus Conference on Guidelines for Hepatitis B and C, Karachi, 16-17th August, 2003.
12. Abbas Z, Muzaffar R, Raza A, et al. Prevalence of genotypes and mutations in the precore and core promoter regions of Hepatitis B virus in patients on hemodialysis and from the community. 20th Annual Congress of Pakistan Society of Gastroenterology. Quetta, April 9-11, 2004.
13. Agboatwalla M, Isomura S, Miyake K, et al. Hepatitis A, B and C seroprevalence in Pakistan. Indian J Pediatr 1994;61:545-9.
14. Haider Z, Khan AA, Rehman K, et al. Sero-diagnosis for viral hepatitis in 93 patients admitted with acute hepatitis in three different teaching hospitals in Lahore. J Pak Med Assoc 1994;44:182-4.
15. Bukhtiari N, Hussain T, Iqbal M, et al. Hepatitis B and C single and co-infection in chronic liver disease and their effect on the disease pattern. J Pak Med Assoc 2003;53:136-40.
16. Stevens CE, Beasley RP, Tsui J, et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-4.
17. Coursaget P, Yvonnet B, Chotard J, et al. Age and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987;22:1-5.
18. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States: Need for alternative vaccination strategies. JAMA 1990;263:1218-22.
19. Beasley RP, Stevens CE, Shiao IS, et al. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975;2:740-1.
20. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985;253:1740-5.
21. Goh, KT. Prevention and control of hepatitis B virus infection in Singapore. Ann Acad Med Singapore 1997;26:671-81.
22. Burk RD, Hwang LY, Ho GY, et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994;170:1418-23.
23. Dodd, RY. The risk of transfusion-transmited infection (editorial). N Engl J Med 1992;327:419-21.
24. Luby S, Khanani R, Zia M, et al. Evaluation of blood bank practices in Karachi, Pakistan, and the government's response. Health Policy Plan 2000;15:217-22.
25. Maynard, JE. Hepatitis B: global importance and need for control. Vaccine 1990;8 (Suppl):S18-20.
26. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263:1218-22.
27. Baqi S, Shah SA, Baig MA, et al. Seroprevalence of HIV, HBV, and syphilis and associated risk behaviours in male transvestites (Hijras) in Karachi, Pakistan. Int J STD AIDS 1999;10:300-4.
28. Usman HR, Akhtar S, Rahbar MH, et al. Injections in health care setting: a risk factor for acute hepatitis B infection in Karachi. Epideiol Infect 2003;130:293-300.
29. Khan AJ, Luby SP, Fikree F, et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull World Health Organ 2000;78:956-63.
30. Mujeeb SA, Khatri Y, Khanani R. Frequency of parenteral exposure and seroprevalence of HBV, HCV, and HIV among operation room personnel. J Hosp Infect 1998;38:133-7.
31. Gerberding, JL. The infected health care provider. N Engl J Med 1996;334:594-5.
32. Aziz S, Memon A, Tily HI, et al. Prevalence of HIV, hepatitis B and C amongst health workers of Civil Hospital Karachi. J Pak Med Assoc 2002;52:92-4.
33. Harpaz R, Seidlein LV, Averhoff FM, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996;334:549-54.
34. Dienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in hospital personnel: Infection or immunization? Am J Epidemiol 1982;115:26-39.
35. Hallower J, Kane M, McCloy E (Eds). Eliminating Hepatitis B as an occupational hazard. London: Medical Imprint 1993, p. 114.
36. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBlgM(-) organ donors. Transplantation 1995;59:230-4
37. Villa E, Rubbiani L, Barchi T, et al. Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage. Lancet 1982;2:1243-4.
38. Kim YI, Heathcote J, Wanless IR. The hepatitis B carrier state - a follow-up study of 100 consecutive cases. Clin Invest Med 1987;10:383-7.
39. Chevillotte G, Durbec JP, Gerolami A, et al. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis: An epidemiologic study. Gastroenterology 1983;85:141-5.
40. Imanishi T, Morikawa S, Ohmagari K, et al. [The effect of habitual alcohol drinking on the development of type B chronic hepatitis, liver cirrhosis and hepatocellular carcinoma]. Nippon Shokakibyo Gakkai Zasshi 1988;85:692-8.
41. Chung HT, Lai CL, Wu PC, et al. Synergism of chronic alcoholism and hepatitis B infection in liver disease. J Gastroenterol Hepatol 1989;4:11-16.
42. Lok ASF. Chronic hepatitis C. N Engl J Med 2002;346:1682-3.
43. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors of chronic hepatitis type B. Gut 1991;32:294-8.
44. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients. J Hepatol 1998;28:930-8.
45. Fattovich G, Brollo L, Alberti A, et al. Long term follow-up of anti-HBe positive chronic active hepatitis B. Hepatology 1988;8:1651-4.
46. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-70.
47. Perillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-22.
48. Chan HL, Tsang SW, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002;97:406-12.
49. Liaw YF. Management of patients with chronic hepatitis B. J. Gastroenterol Hepatol 2002;17:406-8.
50. Asian-Pacific Consensus Statement on management of chronic hepatitis B: an update. J. Gastroenterol Hepatol 2003;18:239-45.
51. Heathcoat J. Treatment of HbeAg positive chronic hepatitis B. Sem Liver Dis 2003;23:69-79.
52. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
53. Rizzetto M. Efficacy of lamivudine in HbeAg-Negative chronic hepatitis B. J. Med Viral 2002;66:435-51.
54. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HbeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.
55. Lok ASF. Practice guidelines: chronic hepatitis B. Hepatology 2001;34:1225-41.
56. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: anti viral efficacy and viral resistance. Am J. Gastroenterol 2002;97:1618-28.
57. EASL International Consensus Conference on hepatitis Br J Hepatol 2003;38:533-40.
58. Ministry of Health, Annual report, Director General Health, 2001-2002, Government of Pakistan 2002.
59. Wong VC, Ip HM, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Lancet 1984;1:921-6.
60. Mast EE, Williams IT, Alter MJ, et al. Hepatitis B vaccination of adolescent and adult high-risk groups in the United States. Vaccine 1998;16 (Suppl):S27-9.
61. Nasir K, Khan KA, Kadri WM, et al. Hepatitis B vaccination among health care workers and students of a medical college. J Pak Med Assoc 2000;50:239-43.
62. Poland GA. Hepatitis B immunization in health care workers. Dealing with vaccine nonresponse. Am J Prev Med 1998;15:73-7.
63. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-14.
64. Liao SS, Li RC, Li H, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: A 15-year follow-up study among Chinese children. Vaccine 1999;17:2661-6.
65. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989;261:2362-6.
66. West DJ, Watson B, Lichtman J, et al. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Pediatr Infect Dis J 1994;13:745-7.
67. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000;355:561-5.
68. Haq N, Hasnain SS, Umar M, et al. Immunogenicity of 10 and 20 μg hepatitis B vaccine in a two-dose schedule. Vaccine 2003;21:3179-85.
69. Update: recommendations to prevent hepatitis B virus transmission - United States. MMWR Morb Mortal Wkly Rep. 1999, Jan 22;48:33-4.
70. Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11 to 15 years. MMWR Morb Mortal Wkly Rep 2000;49:261-3.
71. Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimenfor adolescents: two doses 12 months apart. Vaccine 2002;20:29-30, 3472-6.
72. Zuberi BF, Rajput MR, Muzaffar L, et al. Efficacy of low dose ntra-dermal hepatitis B vaccination schedule. J Pak Med Assoc 1998;48:377-8.
73. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. Donor Study. N Engl J Med 1996;334:1685-90.
74. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989;7:425-30.
75. American Academy of Pediatrics and American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care, 4th edition. Washington DC: 1997, p. 286.
76. Peces R, de la Torre M, Alcazar R, et al. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997;29:239-45.
77. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs. Hepatology 1988;8:766-70.